Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies Raises Price Target on Bellicum Pharma (BLCM) to $22; Reiterates Buy
August 9, 2016 9:50 AM EDTJefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following the company's 2Q earnings report. BLCM reported a Q2 GAAP EPS of ($0.61) vs. estimates of ($0.59).
Analyst Biren Amin commented, "BLCM reported 2Q financial results... More
Bellicum Pharma (BLCM) Misses Q2 EPS by 4c
August 8, 2016 5:06 PM EDTBellicum Pharma (NASDAQ: BLCM) reported Q2 EPS of ($0.61), $0.04 worse than the analyst estimate of ($0.57).
For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.
... More